KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Net Income towards Common Stockholders data on record, last reported at $25.7 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 82.1% year-over-year to $25.7 million; the TTM value through Dec 2025 reached $156.1 million, down 31.06%, while the annual FY2025 figure was $391.0 million, 72.66% up from the prior year.
  • Net Income towards Common Stockholders reached $25.7 million in Q4 2025 per ACAD's latest filing, down from $71.8 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $143.7 million in Q4 2024 and bottomed at -$113.1 million in Q1 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$3.1 million, with a median of -$6.7 million recorded in 2021.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 139.34% in 2023, then skyrocketed 2897.22% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$43.1 million in 2021, then increased by 3.29% to -$41.7 million in 2022, then skyrocketed by 209.89% to $45.8 million in 2023, then skyrocketed by 213.87% to $143.7 million in 2024, then tumbled by 82.1% to $25.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were $25.7 million in Q4 2025, $71.8 million in Q3 2025, and $40.2 million in Q2 2025.